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Background. High HIV burden countries have experienced a high burden of pleural TB in HIV-infected patients. Objective.
To review the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. Methods.
A literature search from 1950 to June 2011 in MEDLINE was conducted. Results. Two-hundred and ninety-nine studies were
identiﬁed, of which 30 met the inclusion criteria. The immunopathogenesis as denoted by cells and cytokine proﬁles is distinctly
diﬀerent between HIV and HIV-uninfected pleural TB disease. Adenosine deaminase and interferon gamma are good markers
of pleural TB disease even in HIV-infected patients. HIV-uninfected TB suspects with pleural eﬀusions commonly have a low
yield of TB organisms however the evidence suggests that in dually infected patients smear and cultures have a higher yield. The
Gene Xpert MTB/RIF assay has signiﬁcant potential to improve the diagnosis of pleural TB in HIV-positive patients. Conclusions.
Pleural TB in HIV-infected patients has a diﬀerent immunopathogenesis than HIV-uninfected pleural TB and these ﬁndings in
part support the diﬀerences noted in this systematic review. Research should focus on developing an interferon gamma-based
point of care diagnostic test and expansion of the role of Gene Xpert in the diagnosis of pleural TB.
1.Background
The World Health Organization reported 1.1 million new
cases of TB among HIV-infected persons in 2009 [1]. High
HIV prevalence regions have experienced a greater burden
of extrapulmonary TB [1]. Extrapulmonary TB is more
common in HIV-infected patients compared with patients
without HIV infection [2, 3] and its incidence has doubled
since the beginning of the HIV pandemic [4]. Furthermore,
pleural TB is the second most common form of extra-
pulmonary TB after peripheral lymph nodes in HIV-
infected patients [4]. Pleural TB in the context of HIV
continues to provide formidable challenges to clinicians
around the world. In this systematic review, we report the
epidemiology, immunopathogenesis, clinical presentation,
diagnosis, and management of tuberculous pleural eﬀusions
in HIV-positive patients and explore some of the important
diﬀerences between them and HIV-uninfected patients as
well as how these ﬁndings could be applied in resource poor
settings.
2. Methods
The PRISMA guidelines for systematic reviews [34]w e r e
used to formulate this paper.
2.1. Eligibility Criteria. Studies were included if all of the
following criteria were met: (1) all study types except case
reports published in English, French, Spanish, and Arabic
and (2) pleural tuberculosis were deﬁned by one of the
following features: (a) positive culture of the pleural ﬂuid
or pleural biopsy specimen or both for M. tuberculosis, (b)
positive sputum culture for M. tuberculosis and pleural eﬀu-
sion, positive acid fast bacilli (AFB) stain of the pleural ﬂuid,
or pleural biopsy specimen, or (c) granuloma on pleural
biopsy with no alternative diagnosis and improvement on2 Clinical and Developmental Immunology
antituberculous therapy. (3) HIV infection documented by
at least serological testing.
2.2. Search Strategy. Al i t e r a t u r es e a r c hi nM E D L I N Ew a s
conducted by one of the investigators (AA). Articles were
limited to English, French, Spanish, and Arabic pub-
lished between 1950 to June 2011. Using Boolean operator
“and”, we combined the following research themes (1)
(“Tuberculosis, Pleural/complications” [Mesh] or “Tuber-
culosis Pleural/diagnosis” [Mesh] or “Tuberculosis, Pleu-
ral/ drug therapy” [Mesh] or “Tuberculosis, Pleural/enzy-
mology” [Mesh] or “Tuberculosis, Pleural/epidemiology”
[Mesh] or “Tuberculosis, Pleural/microbiology” [Mesh] or
“Tuberculosis, Pleural/mortality” [Mesh] or “Tuberculosis,
Pleural/pathology” [Mesh] or “Tuberculosis, Pleural/radio-
graphy” [Mesh] or “Tuberculosis, Pleural/surgery” [Mesh]
or “Tuberculosis, Pleural/therapy” [Mesh]) or pleural tuber-
culosis [Text Word] and (2) “HIV Infections” [Mesh] or HIV
infection [Text Word].
Wealsoscannedthebibliographiesofkeyarticlestoiden-
tifyadditionalstudies.Theliteraturesearchwascrosschecked
by the university librarian to ensure reproducibility and that
no other citations existed.
2.3. Study Selection and Data Collection Process. One re-
viewer (AA) screened the titles and abstracts of identiﬁed
records. Articles were retrieved for full text review if they
contained any information related to pleural tuberculosis
and HIV infection. Full text review of these articles was
performed by two reviewers (AA, GGA) independently using
predeﬁned case report forms. The two reviewers then met to
discuss each article using the predeﬁned case report forms.
Diﬀerences were resolved by consensus. Variables that were
collectedincluded:incidence,prevalence,immunopathogen-
esis, diagnosis, management, and treatment of pleural TB in
HIV-infected patients.
3. Results
3.1. Study Selection. Figure 1 outlines the identiﬁcation,
screening, eligibility, and inclusion of studies in this system-
atic review. The initial search strategy identiﬁed 295 poten-
tiallyrelevantarticlesandfouradditionalstudiesfromreview
of bibliographies. 63 articles were chosen based on titles and
abstracts. 30 articles fulﬁlled the eligibility criteria and 33
articles were excluded after full text reviews. Selection and
information bias, lack of uniform reporting, and inclusion of
low methodological quality studies prevented a formal meta-
analysis. Table 1 shows the characteristics of the 30 included
studies.
4. Epidemiology of Pleural TB in
HIV-InfectedPatients
The prevalence rate of HIV-pleural tuberculosis was highest
in the African regions compared to other regions (Table 2).
The highest rate was in Zimbabwe where 85% of patients
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Figure 1: Identiﬁcation, screening, eligibility, and inclusion of
studies.
with tuberculous pleural eﬀusions in one study were HIV-
positive [16] and the lowest rate was seen in another study
done in Spain at 10% [15]. Although the study populations
were heterogeneous, it can be extrapolated that due to the
fact that the WHO estimates that 37% of dually infected
incident cases came from the African region [1], it would
be expected that more pleural TB would be seen in these
r e g i o n s .M a l e sw e r em o r ef r e q u e n t l yi n f e c t e dw i t hH I Va n d
there was no gender diﬀerences noted between HIV-positive
compared with HIV-uninfected individuals [18, 23, 24].
5. Immunopathogenesis of Pleural TB in
HIVInfectedPatients
Pleural TB has been characterized as a systemic inﬂamma-
tory response which in some HIV-uninfected patients has
been documented to resolve without the use of antibiotics
[36]. This systemic inﬂammatory response likely contributes
to the constellation of symptoms seen in these patients
which can be more severe than in pulmonary TB [37].
The development of a pleural eﬀu s i o ni ni m m u n o c o m p e t e n t
hosts is associated with an intense cell-mediated immune
response with inﬁltration of CD4 T cells and production
of high levels of proinﬂammatory cytokines such as gamma
interferon (IFN-) and tumor necrosis factor alpha (TNF-
α)[ 36, 38]. In contrast, the immunopathogenesis of pleural
TB in HIV-infected patients is diﬀerent because of the
CD4 T cell depletion and subsequent reduction in antigen-
speciﬁc cytokine responses [39]. HIV-infected patients have
decreased numbers s of CD4+ T cells and cytokine responses
to TB [40–43]. When these immunological components are
lacking the key protective immune response is signiﬁcantlyClinical and Developmental Immunology 3
Table 1: Characteristics of included studies.
Study/reference Year
No of pleural TB patients
Design Recruitment of patients
HIV+ HIV−
Aderaye et al. [5] 1996 8 54 Prospective cohort Consecutive
Batungwanayo et al. [6] 1993 28 82 Prospective cohort Consecutive
Cordero et al. [7] 1995 12 107 Retrospective chart review N/A
Dheda et al. [8] 2009 38 13 Prospective cohort Consecutive
Dheda et al. [9] 2009 20 31 Prospective cohort Consecutive
Domoua et al. [10] 2007 30 17 Prospective cohort Consecutive
Elliott et al. [11] 1993 57 13 Prospective cohort Consecutive
Frye et al. [2] 1997 22 169 Retrospective chart review N/A
Gil et al. [12] 1995 10 93 Retrospective chart review N/A
Heyderman et al. [13] 1998 63 11 Prospective cohort Consecutive
Hodsdon et al. [14] 2001 66 29 Prospective cohort Consecutive
Luzze et al. [15] 2001 109 33 Prospective cohort Consecutive
Riantawan et al. [16] 1999 37 52 Prospective cohort Consecutive
Richter et al. [17] 1994 65 47 Prospective cohort Consecutive
Richter et al. [18] 1994 49 26 Prospective cohort Consecutive
Trajman et al. [19] 1997 13 30 Cross-sectional
retrospective N/A
Villena et al. [20] 1996 9 41 Prospective cohort N/A
Baba et al. [21] 2008 16 2 Retrospective case series N/A
Baba et al. [22] 2008 145 20 Retrospective case control N/A
Baba et al. [23] 2008 5 23 Prospective cohort Consecutive
Bezuidenhout et al. [24] 2009 6 6 Case series N/A
Collins et al. [25] 2007 8 0 Case series N/A
Conde et al. [26] 2003 13 71 Prospective cohort Consecutive
Hirsch et al. [27] 2001 16 8 Prospective cohort Consecutive
Jones et al. [28] 2000 3 0 Case series N/A
Elliott et al. [29] 2004 197 0 Randomized controlled
Trial Consecutive
Tshibwabwa-Tumba et al. [30] 1997 159 68 Prospective cohort Consecutive
Toossi et al. [31] 2011 20 20 Prospective cohort Consecutive
Siawaya et al. [32] 2009 12 11 Case series N/A
Mayanja-Kizza et al. [33] 2009 20 0 Case series N/A
N/A: not mentioned in the methods section of the paper.
weakened. T helper 1 type cells secrete TNFα,I F N γ,I L -
2, and IL12. These cells are important in the delayed type
hypersensitivity reaction and in activating macrophages in
pleural TB. Furthermore, granuloma formation is mediated
by CD4+ T cells of the T helper 1 type.
5.1. Histopathology. In an early study done in Tanzania [35],
36 HIV TB pleural biopsies were compared with 21 HIV-
uninfectedTB-pleuralbiopsies.Histologicalcharacterization
of the tissue reaction in pleural biopsies were examined
as follows: reactive (well-formed granulomas with caseous
necrosis, epitheliod cells, giant cells, scarce acid fast bacilli,
or undetected AFB), hyporeactive (poorly formed granu-
lomas with noncaseous necrosis, few epithelioid cells or
macrophages, and no giant cells, AFB were easily seen)
andnon-reactive(notruegranulomaformation,noncaseous
necrosis with nuclear debris and neutrophils, no giant
cells and numerous AFB). Although CD4 counts were not
done in this study, HIV-positive patients had signiﬁcantly
more pleural biopsies demonstrating the hyporeactive and
nonreactive patterns than HIV-uninfected patients (14/36
versus 2/21 P<0.02) and their level of immunodeﬁciency
was worse than those with reactive patterns among the HIV-
infected patients as evidenced by a greater number of AIDS4 Clinical and Developmental Immunology
Table 2: Reported prevalence rates of HIV-pleural tuberculosis
across various studies/countries.
Study/year Country Prevalence
Heyderman et al. 1998 [13] Zimbabwe 85%
Batungwanayo et al. 1993 [6] Rawanda 80%
Luzze et al. 2001 [15] Uganda 80%
Domoua et al. 2007 [10] Ivory Coast 63%
Richter et al. 1994 [18] Tanzania 58%
Riantawan et al. 1999 [16] Thailand 37%
Elliott et al. 1993 [11] Zambia 31%
Trajman et al. 1997 [19] Brazil 30%
Aderaye et al. 1996 [5] Ethiopia 22%
Frye et al. 1997 [2] USA 11%
Gil et al. 1995 [12] Spain 10%
Cordero et al. 1995 [7] Spain 8%
related complications. Furthermore, hyporeactivity in the
HIV group seemed to show a trend towards a mortality
risk (3/11 versus 1/18 deaths). In contrast, a case series of
12 patients (6 HIV-positive and 6 HIV uninfected) more
necrotic granulomas were seen in HIV-positive patients with
pleural TB [24].
In a case series of three HIV-pleural TB cases [28], a
signiﬁcant number of mesothelial cells were noted in the
pleuralﬂuid.Commonly,fewmesothelialcellsareseeninthe
pleural space in patients with pleural TB since it is believed
that there is extensive chronic inﬂammation that covers the
mesothelium preventing it from exfoliating these cells into
the pleural ﬂuid.
5.2. Cytokine Proﬁles in Pleural TB in HIV-Infected Patients.
Cytokine proﬁles in the pleural ﬂuid of pleural TB in
HIV-infected patients versus TB-pleural patients showed a
mostly Th1 (or proinﬂammatory, instead of the Th2 or
anti-inﬂammatory) cytokine proﬁle [31]. No diﬀerences
were found in the levels or patterns of cytokines in pleural
ﬂuid between HIV-positive and negative patients except
for higher IL-8 levels seen in dually infected individuals
[31]. In another study, comparing HIV-uninfected and HIV-
positive pleural TB patients, 29 cytokines were measured in
the plasma and pleural ﬂuid. IL-1β, IL-10, and TNFα were
signiﬁcantly decreased in the pleural ﬂuid of HIV-positive
pleural TB patients [32]. In addition, two proinﬂammatory
markers, CXCL10/IP-10 and CCL3/MIP-1α,m e a s u r e di n
the plasma were characteristic of pleural TB [32]. However,
HIV infection aﬀected the diagnostic accuracy as evidenced
by a shift in cutoﬀ values used, resulting in increased
speciﬁcity at the expense of decreased sensitivity in pleural
TB in HIV-infected persons compared to pleural TB in HIV-
noninfected persons [32]. Other studies have shown that the
levels of TNFα and MCP-1 were signiﬁcantly elevated in the
pleural ﬂuid compared with autologous plasma in dually
infected individuals [33]. MCP is a chemokine produced
by ﬁbroblasts and mesothelial cells and is a chemotactic
agent for monocytes and lymphocytes. Both TB and HIV
productscaninducetheproductionofMCP-1.Furthermore,
transcription activation of HIV-1 in situ can be signiﬁcantly
reduced by neutralization of MCP-1; however, only when
TNFα. was not neutralized suggesting a possible relationship
between MCP-1/TNFα [33].
Necrotic granulomas from pleural biopsies done in
coinfected patients with pleural disease showed signiﬁcantly
elevated TNF α-positive cells [24]. Although the authors
acknowledged that this may not have equated to increased
levels of the cytokine, the presence of this marker on the
cells is an important diﬀerence which may explain the
progression of pleural TB in HIV-infected patients in HIV-
infected patients since apoptotic activity has been linked
with TNFα and its continued presence is detrimental to
the cellular environment [44] resulting in caseating necrosis.
In another study, TNFα was elevated in HIV-pleural TB
compared to HIV-uninfected pleural TB but the diﬀerence
was not statistically signiﬁcant [14]. In this same study, IFNγ
was signiﬁcantly elevated in serum and pleural ﬂuid in HIV-
pleural TB compared to HIV-uninfected pleural TB and it
was suggested that CD8+ T cells could be the source which
is supported by another study showing a relative increase
in CD8+ T cells in HIV-positive patients with pleural TB
[14]. However, mycobacterial replication was not controlled
in the pleural space despite high levels of IFNγ.N od i ﬀerence
was seen in the IL-10 levels in the pleural space between the
twogroups[14].Anotherstudy[27]suggestedapoptosisand
levels of IFNγ are increased in HIV-infected patients with
pleural TB; however, this ﬁnding was not unique to HIV TB
and seen in pleural TB alone.
6. ClinicalFeaturesof PleuralTB in
HIV-InfectedPatients
HIV-infected patients with pleural tuberculosis were more
likely to present with fever, [13, 15, 17], dyspnea [17], cough
[15] and signiﬁcant weight loss [15]i nc o m p a r i s o nw i t h
HIV-uninfected patients. Furthermore, systemic symptoms
and signs such as fatigue, night sweats, diarrhea, lym-
phadenopathy, splenomegaly, and hepatomegaly were more
common in HIV-infected patients [13]compared to HIV-
uninfected patients [45]. Bilateral pleural eﬀusions were also
more frequently reported in HIV-positive patients [5]b u t
the size or location of pleural eﬀusions were comparable
[5,13,15].HIV-positivepatientsthatpresentwithpleuralTB
are generally sicker than non HIV-uninfected individuals as
reﬂected by the increased frequency of systemic symptoms.
Symptoms alone are limited in their ability to diagnose
pleural TB in HIV-positive patients due to their non speciﬁc
nature [13]. The severity of symptoms at presentation may
reﬂect the higher degree of impairment in the immune
systeminHIV-positivepatientswhichleadstomoredissemi-
natedformsofthediseaseresultinginmoreadvanceddisease
at presentation.
7.Diagnosis
7.1. Pleural Fluid. Pleural ﬂuid examination showed in-
creased mesothelial cells [28], decreased albumin and higherClinical and Developmental Immunology 5
Table 3: Reported yields of diﬀerent tests in HIV-infected patients with pleural TB.
Study and year Pleural ﬂuid
smear
∗Pleural ﬂuid
culture
Pleural biopsy
smear
∗Pleural biopsy
culture
Pleural biopsy
histology Sputum culture
Elliott al. 1993 [11] 0% 26% NR 11% 52% NR
Richter et al. 1994 [18] 6% 43% 20% 35% 86% NR
Luzze et al. 2001 [15] NR 43% NR NR 57% NR
Conde et al. 2003 [26] 8% 15% 38% 77% 92% 77%
Hirsch et al. 2001 [27] NR 87% NR NR NR NR
Kitinya et al. 1993 [35] 5% 5% 14% 14% NR NR
Heyderman et al. 1998
[13] 18% NR 19% 42% 60% NR
∗Reported yields of cultures using L¨ owenstein-Jensen medium.
NR: not referred for test.
gamma globulinlevels in HIV-infected patients [17]. Lym-
phocyte predominant eﬀusions [15], LDH, protein and
glucose levels did not diﬀer between dually infected patients
with pleural TB [16].
7.2. Mycobacterium TB Identiﬁcation in Pleural Fluid. Ziehl-
Neelsen (ZN) stain [13, 15], liquid culture using BACTEC
[14, 15]a n dL ¨ owenstein-Jensen (LJ) cultures [11, 13, 15,
18, 26, 27, 41] consistently provided a higher yield in HIV-
infected individuals compared to HIV-uninfected individ-
uals. In one study [13], the more immunocompromised
the patient, the higher chance of ﬁnding TB organisms in
the pleural ﬂuid and the pleura itself. A CD4 count of
< 200 ×106/L was associated with a positive pleural ﬂuid
smear(37%versus0%P = 0.0006)andbiopsyZiehl-Neelsen
stain (35% versus 7% P = 0.021)[13]. The TB yield of
diﬀerent tests used in tuberculouspleuritis in HIV-infected
patientsis shown (Table 3).
Although many studies looking at nucleic acid ampliﬁ-
cation tests (NAAT) applied to pleural TB in HIV-infected
patients have been done [45] they have shown considerable
variability. However, the new gene xpert MTB/RIF assay is
a signiﬁcant advance in point of care molecular diagnostic
biology [46] that could provide a signiﬁcant improvement
in diagnosing pleural TB in HIV-infected patients with the
added beneﬁt that rifampin resistance is also detected by the
assay and the result can be obtained in 2 hours. Although no
studies have been published in HIV-infected patients with
pleural TB, a retrospective analysis of specimens sent to a
national reference laboratory in Germany for mycobacteria
[47] studied various specimen types including 113 pleural
ﬂuid samples for which the speciﬁcity was calculated at
98.1% and the sensitivity was not calculable.
7.3. HIV Identiﬁcation in Pleural Fluid. HIV viral load in
pleural ﬂuid in dually infected patients has been demon-
strated to be higher in the pleural ﬂuid when compared to
plasma [31]. Another study [33] showed that transcriptional
activity of HIV-1 was signiﬁcantly higher in pleural ﬂuid
mononuclear cells (PFMC) compared to peripheral blood
mononuclear cells (PBMC). Increased HIV viral production
wasseeninthepleuralspaceofHIV-pleuralTBpatientsfrom
activatedHLA-DRmononuclearcellsincludinglymphocytes
and CD14+ macrophages[41]. Another study [25]s ugg es t ed
that HIV-positive patients with pleural TB showed higher
HIV viral replication and heterogeneity which then migrated
to the blood increasing systemic HIV heterogeneity. The
excess viral loads seen in the pleural ﬂuid of HIV-TB-
pleural patients make it an important site to gain a better
understanding of whether the increased levels of virus seen
in the pleural ﬂuid of dually infected patients may aﬀect HIV
progression in these patients. The development of targeted
inhibitors of viral replication in dually infected patients
could oﬀer new insight.
7.4. Pleural Biopsy. Ziehl-Neelsen stain of pleural biopsy
carries signiﬁcantly higher yield in HIV-infected patients
than non HIV in two studies [13, 26] and not signiﬁcantly
higher in other studies [17, 35]. The utility of histological
examination of pleural biopsy was high in HIV-infected
patients where granulomatous inﬂammation or caseous
necrosis was detected in 52%–92%. This ﬁnding was com-
parable with HIV-uninfected patients [11, 13, 15, 17, 26].
7.5. Sputum Culture. Sputum culture yield in pleural tuber-
culosis was reported to be higher in HIV-infected patients,
however this was not statistically signiﬁcant [13, 26]. One
of these studies [26], demonstrated that the yield of spu-
tum cultures using sputum induction in dually infected
patients with pleural TB who could not produce sputum
spontaneously was high even in patients with no pulmonary
ﬁndings on chest radiographs.
The use of the pleural ﬂuid or biopsy smear to diagnose
pleural TB in HIV-infected patientsremains an eﬀective
tool which is widely available and inexpensive especially in
regionswithlimitedresources.Cliniciansoftendonotbother
sending pleural ﬂuid for smear and culture due to their low
yield in the HIV-uninfected patient population; however,
the evidence suggests that in dually infected patients smear
and cultures should play an important role in the diagnostic
process (Table 3). The pleural ﬂuid and pleural biopsy TB
culture yield is higher in HIV-infected patients. This may6 Clinical and Developmental Immunology
suggest that a higher bacillary burden is seen in the pleural
space in HIV-infected patients because TB might cross from
the lung parenchyma to the pleural space with greater ease
as a result of an impaired immune response in the pleural
space. Furthermore, the use of bedside inoculation of pleural
ﬂuid in BACTEC liquid medium provides a better sensitivity
and faster results in HIV coinfection [15]. All of these classic
forms of diagnosing pleural TB are limited in the prolonged
time it takes to obtain results and also from the limited
laboratory access in the clinic/hospital where the patients
are assessed. These diagnostic delays result in signiﬁcant
morbidity and mortality of patients. In regions with limited
resources, a point of care test which could be done at the
bedside on pleural ﬂuid would have a signiﬁcant impact on
the management and outcome of these patients.
7.6. Adenosine Deaminase (ADA). Adenosine deaminase
(ADA) a T lymphocyte enzyme that catalyzes the con-
version of adenosine and deoxyadenosine to inosine and
deoxyinosine, respectively. Two diﬀerent molecular forms
of ADA, ADA 1, and ADA2 have been identiﬁed [48].
ADA1 is found in all cells, with its greatest activity in
lymphocytes and monocytes. ADA2 isoenzyme is found
mainly in monocytes/macrophages. Most of the ADA found
in tuberculous pleural ﬂuid is ADA2, whereas most of the
ADA found in other pleural ﬂuids is ADA1. Testing ADA
levels in the pleural ﬂuid is an easy, inexpensive, and useful
test to establish the diagnosis of pleural TB. ADA retains its
high utility in all HIV-infected patients [16] even patients
with low CD4 counts [22]. ADA improves the accuracy of
diagnosis in HIV-infected patients with pleural TB [16, 17,
22]. In all HIV-infected patients regardless of CD4 counts,
the sensitivity of ADA was 94% when the cutoﬀ value of
30 u/l was used and speciﬁcity of 95% [22]. The positive
likelihood ratio was 18.9 and the negative likelihood ratio
was 0.06 [22]. The sensitivity wasalso highat 96% when the
cutoﬀ value used was 60 u/l in HIV-infected patients [16].
These results were comparable to HIV-uninfected patients
[16].
However, it should be noted that the sensitivity and
speciﬁcity of ADA vary according to the diﬀerent cutoﬀ
levels and also to diﬀerent TB population prevalence. ADA
measurement has a limited value in regions of low TB
prevalence [49] as it can also be elevated in patients with
empyema, lymphoma, lung cancer, rheumatoid arthritis,
systemic lupus erythematosus, brucellosis, and Q fever [50].
In a high HIV and TB prevalence region, the use of ADA at
a higher cut point (47IU/L) compared to the standard cut
point (30IU/L) in which a subgroup of HIV tested patients
were studied, it was noted that ADA increases its speciﬁcity
whileuseofthestandardcutpoint (30IU/L)resultsinlossof
speciﬁcity but an increase in its sensitivity and thus improves
its ability to rule out disease.
A possible explanation for the high levels of ADA even in
HIV-infected patients with low CD4 counts may be related
to the fact that monocytes are not signiﬁcantly aﬀected by
HIV coinfection and they are the primary cells responsible
for the production of isoenzyme ADA-2. Riantawan et al.
[16] documented the best cutoﬀ of ADA at 60 U/L in HIV-
infected patients which provides sensitivity of 95% and
speciﬁcity of 96%. Liang QL et al. [51] published a meta-
analysis in mostly HIV-uninfected patients which included
63 studies documenting sensitivity and speciﬁcity of pleural
ADA in the diagnosisof pleural TB to be 92 and 90%,
respectively [51]. The positive likelihood ratio was 9.03, the
negative likelihood ratio was 0.10, and the diagnostic odds
ratio was 110.08 [51].The most widely accepted cutoﬀ value
for pleural ﬂuid ADAis 40 U/l [50]; however, this cutoﬀ will
likely need to be higher in the HIV population.
7.7. Interferon Gamma. Interferon gamma levels in pleural
tuberculosis were signiﬁcantly higher in both serum and
pleural ﬂuid of HIV-positive patients when compared with
HIV-uninfected patients [14]. There was no statistically
signiﬁcant correlation between blood CD4 cell count and
the level of pleural INF-gamma [14, 21]b u tap o s i t i v ec o r -
relation with pleural ﬂuid viral loads was noted (correlation
coeﬃcient 0.54, P = 0.02) [14]. Another study documented
interferon gamma sensitivity of 99% and speciﬁcity of 98%
using 3.7 U/mL cutoﬀ point which did not diﬀer between
HIV-positive and HIV-uninfected patients [20]. In a meta
analysisof27studiesevaluatingtheroleofinterferongamma
release assays (T-SPOT.TB1, QFT-G-IT), and Tuberculin
Skin Test (TST) in diagnosing active tuberculosis [52], 5
studies used IGRA tests for the diagnosis of pleural TB
[8, 21, 53–55]. None of these studies tested all of the patients
entering the respective studies for HIV and all were limited
by small sample sizes. However, one study [8] did test most
of the cohort for HIV (51/67) and managed to conﬁrm that
even in a high HIV burden region, unstimulated pleural
ﬂuid interferon gamma levels measured in TB suspects were
found to be highly sensitive and speciﬁc for distinguishing
pleural TB from non-TB eﬀusions [8]. In the same study
it was also shown that because many HIV-positive patients
likely have paucicellular pleural inﬂammation, adequate
volumes of pleural ﬂuid need to be obtained (>20mL) in
order to obtain adequate number of cells to analyze [8].
Interferon gamma inducible protein of 10kDa (IP-10) and
lipoarabinomannan (LAM) mycobacterial antigen-detection
assay were not useful in discriminating pleural TB patients
versus non-TB patients in a subset of HIV-infected patients;
however,futureworkshouldfocusonvalidatingIP-10ability
to rule out pleural TB [9]. The impact of immunosupression
seen in HIV infection on the diagnostic accuracy of pleural
mononuclear cells and their capacity to secrete interferon
gammarequiresfurtherstudyinlargerstudiestoconﬁrmthe
accuracy of the ﬁndings presented.
Pleural TB in HIV-infected patients remains a challenge
to diagnose because often sputum smears and cultures are
negative. Thoracentesis is commonly performed to examine
the composition of the pleural ﬂuid. However, biochemical,
histological and microbiological examination is usually
limited in low-resource countries. A single point of care test
that could be applied to pleural ﬂuid would have enormous
impact on the diagnosis and management of these cases.Clinical and Developmental Immunology 7
8. Treatment
There is no evidence to suggestthat HIV-pleural tuberculosis
should be treated diﬀerently than pulmonary TB. Two
months of isoniazid, rifampin, pyrazinamide and ethambu-
tol followed by 4 months of isoniazid and rifampin for sus-
ceptible organisms to all ﬁrst line drugs are the international
standard [56].
It is recommended that antiretroviral therapy should
be delayed for 2 months unless the CD4 < 100× 106/L to
preventimmunereconstitutionsyndromewhichcouldoccur
in one-third of patients [57]. The use of rifabutin instead
of rifampin is recommended to avoid drug interaction
with protease inhibitors and most nonnucleoside reverse
transcriptase inhibitors, with the exception of efavirenz.
Even so, rifampin-containing regimens can be prescribed
if the selected antiretroviral drugs include efavirenz and
two nucleoside transcriptase inhibitors (e.g., tenofovir and
emtricitabine) [50]. In one randomized controlled study of
197 patients with HIV associated pleural TB, the adminis-
tration of prednisolone as adjunctive therapy to standard
ﬁrst line TB therapy did not result in a survival beneﬁt
and although it was associated with faster resolution of the
TB it was also associated with an increased risk of Kaposi
sarcoma [29]. The patients in this study were signiﬁcantly
immunocompromised and the eﬀects of steroids on HIV-
infected patients with CD4 counts >200 × 106/L still need
to be assessed. A recent Cochrane review found no clear
evidence to support the use of adjunctive corticosteroids in
all persons with TB-pleural eﬀusion [58].
9.Q ualityo fI nc l ud edS tudies
Many of the studies had small sample sizes and did not
have consecutive recruitment of patients which may have
resulted in selection and information bias. Furthermore, the
study design limited the quality of several studies with only
one randomized controlled trial, several prospective cohorts,
some retrospective chart reviews and several case series.
Another signiﬁcant limitation is the fact that many of the
HIV-infected patients had diﬀerent levels of immunosup-
pression (diﬀerent levels of CD4 cells) which could aﬀect the
immunopathogenesis studies.
10. Reasons for Exclusionof Studies
Many of the studies that were excluded from this analysis did
not establish the diagnosis of pleural TB or HIV accurately.
One common reason for exclusion was that the patients
in the HIV-uninfected group were not tested for HIV and
assumed to be HIV uninfected. Some of the earlier studies
opted to make a clinical diagnosis of HIV instead of getting
serological testing which may have not been available at the
time of the study. Other studies categorized pulmonary TB
in the same category as pleural TB, whereas we categorized
it as extrapulmonary disease with speciﬁc criteria depicted in
the inclusion criteria section. Several studies were excluded
because they were case reports.
11.FutureResearch
Pleural TB in HIV-infected patients has a diﬀerent immu-
nopathogenesis than HIV-uninfected pleural TB and these
ﬁndingsinpartsupportthediagnosticdiﬀerencesseeninthe
yield of TB in the pleura in HIV-infected patients compared
to HIV-uninfected patients. More research is needed in the
ﬁeld of immunopathogenesis of HIV-pleural TB disease as
it oﬀers an important microcosm where the bacteria and
virus interact allowing the study of this complex interaction
between HIV and TB to be further elucidated. Furthermore,
theimmunopathogenicdiﬀerencesmayhelpdevelopabetter
interferon gamma-based point of care test that could be used
at the bedside on pleural ﬂuid in low-resource countries
with high HIV prevalence. The Gene Xpert MTB/RIF assay
technology applied to pleural ﬂuid is a formidable area of
research which could have enormous impact on the early
diagnosis of pleural TB in HIV-positive patients and should
be deemed a research priority in this ﬁeld.
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